HIT Consultant August 11, 2021
Jasmine Pennic

What You Should Know:

Reify Health, a Boston-based company paving the way to faster, predictable, and more accessible clinical trials, today announced it has raised $220M in a Series C funding round led by Coatue Management, joined by ICONIQ Growth and Adams Street Partners, as well as existing investors Sierra Ventures and Battery Ventures. This latest funding brings the company’s valuation to $2.2B.

– Reify Health has built a new foundation for how clinical trials are run through its business entities, StudyTeam and Care Access. StudyTeam delivers the best-in-class technology platform for optimizing patient recruitment and enrollment, and is used by top-20 global biopharma companies such as Amgen, AstraZeneca, and Eli Lilly and Company, and approximately 4,000 research sites...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma, Pharma / Biotech, Trends
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Walgreens Suffers $6 Billion Loss As VillageMD Clinic Investment Sours

Share This Article